This phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients age 70 years and older with hormone receptor positive, HER2 negative breast cancer that has spread to other places in the body.
Documented informed consent of the participant
Age >= 70 years
Life expectancy > 6 months
Ability to read and understand English or Spanish
Major surgery within 14 days prior to receiving study drug or has not recovered from major side effect
Patient is currently receiving any of the prohibited medications detailed below and cannot be discontinued 7 days prior to starting study drug
Other investigational therapy should be given to participants
Anticancer agents other than the study medications administered as part of this study protocol should be given to participants. If such agents are required for a participant then the participant must first be withdrawn from the study
City of Hope Medical Center
Lead sponsor
National Cancer Institute (NCI)
Collaborator